YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells

Yao Ting Huang, Shiow Lin Pan, Jih Hwa Guh, Ya Ling Chang, Fang Yu Lee, Sheng Chu Kuo, Cheng Ming Teng

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Although the indazole compound, YCA, is reported to exert anticancer activities in several cancer cell types, its target and mechanism of action have not been well explored. The objectives of this study were to ascertain whether YC-1 directly induces apoptosis in prostate cancer cells and to explore the mechanism(s) whereby YC-1 causes cell death. Hormone-refractory metastatic human prostate cancer PC-3 cells were selected for this study. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay indicated that YC-1 suppresses growth of PC-3 cells in a concentration-dependent and time-dependent manner. Apoptosis was determined using 4′,6-diamidino-2-phenylindole staining, and cell cycle progression was examined by FACScan flow cytometry. YC-1 treatment showed chromatin condensation and increased the percentage of PC-3 cells in the hypodiploid sub-G0-G1 phase, indicative of apoptosis. Additionally, exposure to YC-1 was found to induce activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase. Translocation and activation of nuclear factor-κB (NF-κB) were determined by immunofluorescent staining and ELISA, respectively. The results showed that YC-1 abolished constitutive nuclear translocation and activation of NF-κB/p65. Furthermore, inhibition of inhibitor of κBα (IκBα) phosphorylation and accumulation of IκBα were observed. The antitumor effects of YC-1 were evaluated by measuring the growth of tumor xenografts in YC-1-treated severe combined immunodeficient mice. The volumes of PC-3 tumors produced in severe combined immunodeficient mice were observed to decline significantly after treatment with YCA compared with vehicle controls. We concluded that the antitumor effects of YC-1 in PC-3 cells include the induction of apoptosis and the suppression of NF-κB activation. Given these unique actions, further investigations of the effects of YC-1 against hormone-refractory prostate cancer are warranted.

Original languageEnglish
Pages (from-to)1628-1635
Number of pages8
JournalMolecular Cancer Therapeutics
Volume4
Issue number10
DOIs
Publication statusPublished - Oct 2005
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Apoptosis
SCID Mice
Indazoles
Hormones
Staining and Labeling
Neoplasms
Cell Cycle Resting Phase
Poly(ADP-ribose) Polymerases
G1 Phase
Growth
Heterografts
Caspase 3
Chromatin
Cause of Death
Cell Cycle
Flow Cytometry
Cell Death
Enzyme-Linked Immunosorbent Assay
Phosphorylation

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells. / Huang, Yao Ting; Pan, Shiow Lin; Guh, Jih Hwa; Chang, Ya Ling; Lee, Fang Yu; Kuo, Sheng Chu; Teng, Cheng Ming.

In: Molecular Cancer Therapeutics, Vol. 4, No. 10, 10.2005, p. 1628-1635.

Research output: Contribution to journalArticle

Huang, Yao Ting ; Pan, Shiow Lin ; Guh, Jih Hwa ; Chang, Ya Ling ; Lee, Fang Yu ; Kuo, Sheng Chu ; Teng, Cheng Ming. / YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 10. pp. 1628-1635.
@article{fa879eb2d2b84e3ca93af2eae75f577f,
title = "YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells",
abstract = "Although the indazole compound, YCA, is reported to exert anticancer activities in several cancer cell types, its target and mechanism of action have not been well explored. The objectives of this study were to ascertain whether YC-1 directly induces apoptosis in prostate cancer cells and to explore the mechanism(s) whereby YC-1 causes cell death. Hormone-refractory metastatic human prostate cancer PC-3 cells were selected for this study. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay indicated that YC-1 suppresses growth of PC-3 cells in a concentration-dependent and time-dependent manner. Apoptosis was determined using 4′,6-diamidino-2-phenylindole staining, and cell cycle progression was examined by FACScan flow cytometry. YC-1 treatment showed chromatin condensation and increased the percentage of PC-3 cells in the hypodiploid sub-G0-G1 phase, indicative of apoptosis. Additionally, exposure to YC-1 was found to induce activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase. Translocation and activation of nuclear factor-κB (NF-κB) were determined by immunofluorescent staining and ELISA, respectively. The results showed that YC-1 abolished constitutive nuclear translocation and activation of NF-κB/p65. Furthermore, inhibition of inhibitor of κBα (IκBα) phosphorylation and accumulation of IκBα were observed. The antitumor effects of YC-1 were evaluated by measuring the growth of tumor xenografts in YC-1-treated severe combined immunodeficient mice. The volumes of PC-3 tumors produced in severe combined immunodeficient mice were observed to decline significantly after treatment with YCA compared with vehicle controls. We concluded that the antitumor effects of YC-1 in PC-3 cells include the induction of apoptosis and the suppression of NF-κB activation. Given these unique actions, further investigations of the effects of YC-1 against hormone-refractory prostate cancer are warranted.",
author = "Huang, {Yao Ting} and Pan, {Shiow Lin} and Guh, {Jih Hwa} and Chang, {Ya Ling} and Lee, {Fang Yu} and Kuo, {Sheng Chu} and Teng, {Cheng Ming}",
year = "2005",
month = "10",
doi = "10.1158/1535-7163.MCT-05-0090",
language = "English",
volume = "4",
pages = "1628--1635",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells

AU - Huang, Yao Ting

AU - Pan, Shiow Lin

AU - Guh, Jih Hwa

AU - Chang, Ya Ling

AU - Lee, Fang Yu

AU - Kuo, Sheng Chu

AU - Teng, Cheng Ming

PY - 2005/10

Y1 - 2005/10

N2 - Although the indazole compound, YCA, is reported to exert anticancer activities in several cancer cell types, its target and mechanism of action have not been well explored. The objectives of this study were to ascertain whether YC-1 directly induces apoptosis in prostate cancer cells and to explore the mechanism(s) whereby YC-1 causes cell death. Hormone-refractory metastatic human prostate cancer PC-3 cells were selected for this study. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay indicated that YC-1 suppresses growth of PC-3 cells in a concentration-dependent and time-dependent manner. Apoptosis was determined using 4′,6-diamidino-2-phenylindole staining, and cell cycle progression was examined by FACScan flow cytometry. YC-1 treatment showed chromatin condensation and increased the percentage of PC-3 cells in the hypodiploid sub-G0-G1 phase, indicative of apoptosis. Additionally, exposure to YC-1 was found to induce activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase. Translocation and activation of nuclear factor-κB (NF-κB) were determined by immunofluorescent staining and ELISA, respectively. The results showed that YC-1 abolished constitutive nuclear translocation and activation of NF-κB/p65. Furthermore, inhibition of inhibitor of κBα (IκBα) phosphorylation and accumulation of IκBα were observed. The antitumor effects of YC-1 were evaluated by measuring the growth of tumor xenografts in YC-1-treated severe combined immunodeficient mice. The volumes of PC-3 tumors produced in severe combined immunodeficient mice were observed to decline significantly after treatment with YCA compared with vehicle controls. We concluded that the antitumor effects of YC-1 in PC-3 cells include the induction of apoptosis and the suppression of NF-κB activation. Given these unique actions, further investigations of the effects of YC-1 against hormone-refractory prostate cancer are warranted.

AB - Although the indazole compound, YCA, is reported to exert anticancer activities in several cancer cell types, its target and mechanism of action have not been well explored. The objectives of this study were to ascertain whether YC-1 directly induces apoptosis in prostate cancer cells and to explore the mechanism(s) whereby YC-1 causes cell death. Hormone-refractory metastatic human prostate cancer PC-3 cells were selected for this study. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay indicated that YC-1 suppresses growth of PC-3 cells in a concentration-dependent and time-dependent manner. Apoptosis was determined using 4′,6-diamidino-2-phenylindole staining, and cell cycle progression was examined by FACScan flow cytometry. YC-1 treatment showed chromatin condensation and increased the percentage of PC-3 cells in the hypodiploid sub-G0-G1 phase, indicative of apoptosis. Additionally, exposure to YC-1 was found to induce activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase. Translocation and activation of nuclear factor-κB (NF-κB) were determined by immunofluorescent staining and ELISA, respectively. The results showed that YC-1 abolished constitutive nuclear translocation and activation of NF-κB/p65. Furthermore, inhibition of inhibitor of κBα (IκBα) phosphorylation and accumulation of IκBα were observed. The antitumor effects of YC-1 were evaluated by measuring the growth of tumor xenografts in YC-1-treated severe combined immunodeficient mice. The volumes of PC-3 tumors produced in severe combined immunodeficient mice were observed to decline significantly after treatment with YCA compared with vehicle controls. We concluded that the antitumor effects of YC-1 in PC-3 cells include the induction of apoptosis and the suppression of NF-κB activation. Given these unique actions, further investigations of the effects of YC-1 against hormone-refractory prostate cancer are warranted.

UR - http://www.scopus.com/inward/record.url?scp=27644518437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644518437&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0090

DO - 10.1158/1535-7163.MCT-05-0090

M3 - Article

VL - 4

SP - 1628

EP - 1635

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -